Research programme: Anticancer therapeutics - Generon (Shanghai) CorporationAlternative Names: A-337
Latest Information Update: 30 Aug 2016
At a glance
- Originator Generon (Shanghai) Corporation
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action CD3 antigen stimulants; Epithelial cell adhesion molecule modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours